




Sociedad Española
de Reumatología -
Colegio Mexicano
de Reumatología

Reumatología Clínica

www.reumatologiaclinica.org



Case Report

Autoimmunity in patients with inborn errors of immunity: A case series



Mariana Gamboa Espíndola,^a Eduardo Martín-Nares,^b Gabriela Hernández Molina^{b,*}

^a Departamento de Medicina Interna, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

^b Departamento de Inmunología y Reumatología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

ARTICLE INFO

Article history:

Received 2 October 2023

Accepted 10 March 2024

Available online 8 July 2024

Keywords:

Primary immunodeficiency

Autoimmunity

Systemic autoimmunity

Innate immunity disorder

ABSTRACT

Objective: To assess the prevalence of systemic and organ-specific autoimmunity among individuals with human inborn errors of immunity (IEI).

Methods: Retrospective study. We recorded demographic variables, type of immunodeficiency, and systemic and organ specific autoimmunity.

Results: We included 48 patients (54.1% men) with mean age of 32.1 years. The most common IEIs included combined immunodeficiency with syndromic features (31.2%) and predominantly antibody deficiency (20.1%). We observed autoimmunity in 15 patients (31.2%): 12 organ-specific autoimmunity and 5 systemic autoimmunity, not mutually exclusive groups. Organ-specific autoimmunity preceded the onset of IEI in 5 patients, was concurrent in one patient, and developed after the diagnosis of IEI in 6 cases. From the systemic autoimmunity group, we observed polyarteritis nodosa ($n=2$), antiphospholipid syndrome (APS) ($n=2$), and overlap of limited systemic sclerosis/APS/Sjögren's syndrome ($n=1$), and in all cases, this occurred after the IEI diagnosis.

Conclusion: Our findings confirm the coexistence of autoimmunity and IEI. This overlap may be attributed to B and T cell disorders, as well as potential alterations in the microbiota in these patients.

© 2024 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Autoinmunidad en pacientes con errores innatos de la inmunidad: serie de casos

RESUMEN

Palabras clave:

Imunodeficiencia primaria

Autoinmunidad

Autoinmunidad sistémica

Errores innatos de la inmunidad

Objetivo: Evaluar la prevalencia de autoinmunidad sistémica e inmunidad órgano-específica en pacientes con errores innatos de la inmunidad (EI) en un centro de tercer nivel de atención.

Métodos: Estudio retrospectivo. Se registraron variables demográficas, tipo de inmunodeficiencia, y autoinmunidad órgano-específica y sistémica.

Resultados: Se incluyeron 48 pacientes (54.1% hombres) con edad promedio de 32.1 años. Las EI más frecuentes fueron inmunodeficiencia combinada con características sindrómicas (31.2%) y deficiencia predominantemente de anticuerpos (20.1%). Documentamos autoinmunidad en 15 pacientes (31.2%): 12 órgano-específica y 5 sistémica, grupos no mutuamente excluyentes. La autoinmunidad órgano-específica precedió en 5 pacientes a la EI, en 1 fue concomitante y en 6 posterior. Del grupo de autoinmunidad sistémica observamos poliarteritis nodosa ($n=2$), síndrome antifosfolípido (SAF) ($n=2$) y sobreposición esclerosis sistémica limitada/SAF/Síndrome de Sjögren ($n=1$), y en todos fue posterior a la EI.

* Corresponding author.

E-mail address: gabyhm@yahoo.com (G. Hernández Molina).

Conclusión: Nuestros hallazgos apoyan la coexistencia de autoinmunidad en IEI. Esta coexistencia podría deberse a una alteración inmunológica en células B y T, así como al posible papel de una microbiota alterada en estos pacientes.

© 2024 Elsevier España, S.L.U. y Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares.

Introduction

Inborn errors of immunity (IEI) encompass inherited disorders of the function and regulation of the immune system characterised by increased susceptibility to infections, autoinflammation, lymphoproliferation, granuloma formation, atopy and malignancy.^{1,2} While these patients have been reported to be prone to autoimmunity,³ this has been focused on a specific IEI.

With respect to organ-specific autoimmunity, in a cohort of 562 patients with IEI, 6% had some autoimmune cytopenia.² In contrast, there have been only one-off reports of systemic autoimmunity.

This study has assessed the prevalence of systemic and organ-specific autoimmunity in a cohort of adult patients with IEI.

Material and methods

A retrospective case series of subjects with IEI following the classification of the Committee of Experts of the International Union of Immunological Societies¹ who attended a tertiary public healthcare centre between January 2006 and March 2023 and who had a complete clinical record available for review. Demographic variables, type of immunodeficiency, duration, organ-specific autoimmunity (thyroid, hepatic, renal, dermatological, endocrinological, neurological, and haematological), systemic autoimmunity, and time of debut were all recorded. Descriptive statistics were used based on the distribution of the variables. The study was approved by the Institutional Ethics Committee.

Forty-eight patients (26 males, 54.1%) with IEI, mean current age of 32.1 ± 13 years, and mean time of evolution of 16.9 ± 9.1 years were identified and collected. The most frequent IEIs were combined immunodeficiency with syndromic features (31.2%) and predominantly antibody deficiency (20.1%) (Fig. 1).

We documented systemic and/or organ-specific autoimmunity in 15 patients (31.2%), 12 of which were organ-specific and five were systemic; these groups were not mutually exclusive.

Organ-specific autoimmunity preceded the IEI in five cases (median 7 years, range 1–19), was concomitant in one, and posterior in six (median 4 years, range 1–17). We observed immune thrombocytopenia ($n=3$), autoimmune thyroid disease ($n=5$), alopecia areata ($n=1$), vitiligo ($n=2$), morphea ($n=1$), autoimmune hepatitis ($n=1$), ulcerative colitis ($n=1$), Evans syndrome ($n=2$), pernicious anaemia ($n=1$), and myasthenia gravis ($n=1$).

Of the participants with systemic autoimmunity, we detected polyarteritis nodosa (PAN) ($n=2$), antiphospholipid syndrome (APS) ($n=2$), and limited systemic sclerosis/ SAF/ Sjögren's syndrome (SS) overlap ($n=1$); in all of them, it was following the IEI (median 8 years, range 1–33 years). **Tabla 1** displays the patient characteristics.

Discussion

The CEREDIH registry ($n=2183$) of IEI has documented autoimmune disorders in 26.2% of the patients, with the risk of autoimmune disease being 10 times greater than in the general population, and higher in common variable immunodeficiency (CVID) and T⁴ cell deficiency. The USIDNET cohort of individuals with CVID ($n=870$) reported autoimmunity in 5.9%, most frequently affecting females and non-whites, and not associated with CD19+ B-lymphocyte count, CD4/CD8 ratio or serum immunoglobulins. Most had inflammatory arthritis ($n=18$) and SS ($n=11$), followed by lupus and vasculitis.⁵ Other studies have indicated a prevalence rate of rheumatoid arthritis and juvenile idiopathic arthritis in CVID of 1–5%,^{6–8} and there are isolated cases with inflammatory myopathies and relapsing polychondritis.⁹ In primary antibody deficiencies (CVID and other conditions), up to 16% of patients present with spondyloarthritis-like arthritis or enteropathic arthritis,⁷ whereas in autoimmune polyendocrinopathy with candidiasis and ectodermal dystrophy, SS is most common.¹⁰ As for organ-specific autoimmunity in CVID, gastrointestinal and haematological autoimmunity (haemolytic anaemia, thrombocytopenia, neutropenia, and pernicious anaemia) are the predominant manifestations.^{6,10}

In our study involving a variety of IEIs, we documented 31.2% of systemic and/or organ-specific autoimmunity. The time of onset was variable in the organ-specific autoimmunity group but was after the diagnosis of IEI in all cases of systemic autoimmunity. Our case series exhibited PFS and PAN more frequently, in contrast to the literature.

Conclusion

Our findings corroborate the coexistence of autoimmunity in individuals with IEI. This co-existence may be due to an immunological alteration of B and T cells, or to an alteration of the microbiota.




Fig. 1. Distribution of inborn errors of immunity.

Table 1

Patients with inborn errors of immunity and systemic autoimmune diseases.

Patient	Classification of immunodeficiency	Specific immunodeficiency	Systemic disease	Serology	Treatment	Disease activity
1	Predominantly antibody defects	Common variable immunodeficiency	PAN	None performed	PDN, CFM	Remission
2	Congenital defects of phagocytic function or number of phagocytes	Chronic granulomatous disease	Thrombotic SAF	Anti-β2-glycoprotein I IgM+, anti-cardiolipin IgM+	Anticoagulation	Stable
3	Immunodeficiency combined with syndromic features	Hyper-IgE syndrome	PAN	None performed	PDN, MMF, IVIg	Remission
4	Immunodeficiency combined with syndromic features	Velocardiofacial syndrome	Haematological SAF (Evans syndrome)	Anticardiolipin IgM+	PDN, AZA, RTX, splenectomy	Partial remission
5	Congenital defects of phagocytic function or number of phagocytes	GATA 2 deficiency	Limited systemic sclerosis/ obstetric SAF/ SS	ANA+, anti-centromere+, anti-Ro+, anti-β2-glycoprotein I IgM+	Calcium antagonists, oral lubricants	Stable

ANA: antinuclear antibodies; AZA: azathioprine; CFM: cyclophosphamide; MMF: mycophenolate mofetil; PAN: polyarteritis nodosa; PDN: prednisone; RTX: rituximab; SAF: antiphospholipid syndrome; SS: Sjögren's syndrome.

Funding

This research has received no specific grants from public-sector agencies, the commercial sector, or from non-profit organisations.

Conflict of interests

The authors have no conflict of interests to declare.

References

- Bousfiha A, Moundir A, Tangye SG, Picard C, Jeddane L, Al-Herz W, et al. The 2022 update of IUIS phenotypical classification for human inborn errors of immunity. *J Clin Immunol*. 2022;42:1508–20. <http://dx.doi.org/10.1007/s10875-022-01352-z>.
- Taskin R, Topyildiz E, Karaca N, Aksu G, Karapinar D, Kutukculer N. Autoimmune cytopenias are highly associated with inborn errors of immunity and they may be the initial presentations in cases without severe infections. *Int Arch Allergy Immunol*. 2023;28:1–10. <http://dx.doi.org/10.1159/000535258>.
- Padem N, Wright H, Fuleihan R, Garabedian E, Suez D, Cunningham-Rundles C, et al. Rheumatologic diseases in patients with inborn errors of immunity in the USIDNET registry. *Clin Rheumatol*. 2022;41:2197–203. <http://dx.doi.org/10.1007/s10067-021-06044-4>.
- Fischer A, Provot J, Jais J-P, Alcais A, Mahlaoui N, the members of the CEREDIH French PID study group. Autoimmune and inflammatory manifestations occur frequently in primary immunodeficiencies. *J Allergy Clin Immunol*. 2017;140:1388–93.e8. <http://dx.doi.org/10.1016/j.jaci.2016.12.978>.
- Gutierrez M, Sullivan K, Fuleihan R, the USIDNET Consortium, and Bingham I. Phenotypic characterization of patients with rheumatologic manifestations of common variable immunodeficiency. *Sem Arthritis Rheum*. 2018;48:318–26.
- Azizi G, Kiaee F, Hedayat E, Yazdani R, Dolatshahi E, Alinia T, et al. Rheumatologic complications in a cohort of 227 patients with common variable immunodeficiency. *Scand J Immunol*. 2018;87:e12663.
- Pott N, Atschekzei F, Pott C, Ernst D, Witte T, Sogkas G. Primary antibody deficiency-associated arthritis shares features with spondyloarthritis and enteropathic arthritis. *RMD Open*. 2022;8:e002664.
- Agarwal S, Cunningham-Rundles C. Autoimmunity in common variable immunodeficiency. *Ann Allergy Asthma Immunol*. 2019;123:454–60. <http://dx.doi.org/10.1016/j.anai.2019.07.014>.
- Mucke J, Corner A, Witte T, Schneider M. Association of common variable immunodeficiency and rare and complex connective tissue and musculoskeletal diseases. A systematic literature review. *Clin Exp Rheum*. 2022;40 Suppl 134:S40–5.
- Dimitriades V, Sorensen R. Rheumatologic manifestations of primary immunodeficiency diseases. *Clin Rheumatol*. 2016;35:843–50. <http://dx.doi.org/10.1007/s10067-016-3229-6>.